13345-50-1Relevant articles and documents
Improving the aqueous stability of prostaglandin E2 and prostaglandin A2 by inclusion complexation with methylated-β-cyclodextrins
Hirayama,Kurihara,Uekama
, p. 4237 - 4240 (1984)
-
-
Stork,G.,Raucher,S.
, p. 1583 - 1584 (1976)
-
Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
-
, (2009/05/29)
The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
Lipase-catalysed acylation of prostanoids
Parve, Omar,Jaerving, Ivar,Martin, Ivar,Metsala, Andrus,Vallikivi, Imre,Aidnik, Madis,Pehk, Tonis,Samel, Nigulas
, p. 1853 - 1858 (2007/10/03)
Natural prostaglandins (PG) F(2α) and E1 as well as (+)-cloprostenol were regioselectively 11-acylated using Novozym 435 as a catalyst and vinyl acetate as an acyl donor. Unlike the above compounds the 15-OH group of PGE2 was also acylated with a significant velocity under the same conditions. The enantiospecificity of the lipase-catalysed 11-acetylation of cloprostenol was established by separate treatment of (+)- and (-)-cloprostenols.